
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV is positioned favorably due to its robust pipeline of gene therapies, particularly with the encouraging data from its AMT-130 program for Huntington's disease, which reflects a strong efficacy and biomarker package recognized by the scientific community. Additionally, the positive interim data from the AMT-260 trial for mesial temporal lobe epilepsy and the collaboration with Bristol Myers Squibb for cardiovascular diseases further enhances its growth prospects. The absence of new regulatory concerns regarding manufacturing or safety, combined with a favorable risk-benefit profile for its therapies, reinforces a positive outlook for the company's future financial performance.
Bears say
The analysis indicates a negative outlook on uniQure's stock primarily due to significant delays in the submission timeline for its lead product, AMT-130, which have prompted the company to withdraw previous guidance for a BLA submission that was slated for early 2026. Furthermore, the company faces substantial financial risks as a clinical-stage entity with no revenue-generating products and a history of ongoing losses since its inception, which continues to undermine investor confidence. Increased market competition for similar indications presents an additional challenge that could adversely affect uniQure’s market penetration and pricing strategies, compounding the company’s difficulties in the current environment.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares